Please. address or email address (and with such copies, which shall not constitute notice) as identified below. Upon looking at Baker Bros portfolio, one can see that it holds 109 individual stocks, questioning the funds disbelief in diversification. Shares started trading at ~$24 and currently goes for ~$246. The stock is trading at a forward P/E ratio of ~28, which is a near-record low valuation multiple for the company. Management owns 12 percent of the fund. (m)Enforcement. The filing was for a pooled investment fund: other investment fund The notice included securities offered of Pooled Investment Fund Interests. Baker Bros Advisors was founded in 2000 and is based in New York City. This Agreement shall automatically terminate upon the earliest of (i)such time as San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. These investors may include private investors, venture capital firms, or other investment vehicles. The stock currently trades at $13.72. All text and design is copyright 2020 WhaleWisdom.com. Prior to joining Baker Brothers in 2005, Mr. Goller was an associate of JPMorgan Partners, LLC where he focused on venture investments in the life sciences sector from 1999 to 2003. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. Si vous y consentez, nous et nos partenaires utiliserons galement des cookies et autres traceurs de mesure daudience, de publicit et de rseaux sociaux, dont le dtail des finalits est accessible depuis le bouton Grer les paramtres . Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. Investor will provide the Company, in writing, the information about the Investor Designee that is reasonably required by applicable law for (e)IPO means the Companys first underwritten public Shares plunged by a massive 45%, and they have yet to recover since then. There was a marginal increase in Q1 2021. Except as otherwise provided herein, the provisions hereof shall inure to the The position was rebuilt between Q3 2014 to Q1 2015 at prices between ~$55 and ~$125. Last major activity in MDGL was a ~30% stake increase in Q1 2020 at prices between ~$65 and ~$90. Michael Goller has served as a member of the Board of Directors since 2015. Last major activity was in 2019 when Q2 to Q4 saw a roughly one-third selling at prices between ~$1.60 and ~$8.70. Adjustments. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data. Note: Baker Brothers controls ~6% of the business. Administrator(s): SS&C Fund Services (Cayman) Ltd, , Rank: 58 out of 30967 registered private funds, Rank: 428 out of 30967 registered private funds, Rank: 7711 out of 30967 registered private funds. Note: Baker Brothers controls ~10% of Madrigal Sciences. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Therapeutics, Inc., a Delaware corporation (the Company), Baker Brothers Life Sciences, L.P. (BBLS) and 667, L.P. (667 and together with BBLS, the Investor). $0.0001 per share. ACADIA Pharmaceuticals focuses on the development and commercialization of small molecule drugs aimed at unmet medical needs in central nervous system disorders. There are 20 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. Julian Baker joined the board in January 2021. The cookie is used to store the user consent for the cookies in the category "Other. Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. Julian Baker and Felix Baker 's Baker Bros. Advisors recently filed an amended Form 13D with the SEC to report the sale of common shares of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX). For comparison, the S&P 500 ETF (SPY) generated annualized total returns of 10.2% over the same time period. (1)person designated at any time and from time to time by the Investor (the Investor Designee); provided that, the Company shall have no obligation to support the nomination of or cause the Board of Directors to include in However, most of them comprise risky pre-revenue firms that should only be considered upon having a great understanding of their business model. Baker Bros. Advisors LP 860 Washington Street, 3rdFloor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) January 12, 2023 (Date of event which requires filing of this statement) If the filing person has previously filed a statement on Schedule Additionally, the rights set forth in this Section2(c) may Baker Bros Advisors was founded in 2000 and is based in New York City. Baker Brothers 13F portfolio value remained almost steady at $22.77B this quarter. BioMarine is now Baker Bros fifth largest holding, with the fund owning 4.14% of the companys outstanding shares. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. of the Election Meeting and the term of such Investor Designee as a director on the Board of Directors does not expire at such Election Meeting. Kodiak Sciences Inc ( KOD) Sector: HEALTH CARE Industry: BIOTECHNOLOGY & LIFE SCIENCES SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) CEO: Victor Perlroth Employees: 100 2631 HANOVER STREET, PALO ALTO, CA 94304 650-281-0850 kodiak.com Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. Its stake in Seattle Genetics is up $1 billion since news of. Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. Win whats next. Shares started trading at ~$20 and currently goes for $14.36. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. Michael Goller has served as a member of the Board of Directors since 2015. The stock currently trades at ~$142. Linda Rosenberg Ach P '12. Heron Therapeutics (HRTX): HRTX is a 0.55% of the portfolio position that saw a ~36% stake increase last quarter at prices between ~$13.25 and ~$18.50. Updated on November 23rd, 2022 by Nikolaos Sismanis. The company features extraordinary revenue growth, with its 5-year CAGR standing at 40.6%. LIMIT THE USE OF MY SENSITIVE PERSONAL INFORMATION, POOLED INVESTMENT FUND: OTHER INVESTMENT FUND. Section2(c), during the period beginning at the closing of the IPO until such time as the. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. Unlike many biotech companies, which are pre-revenue, Incyte has been growing its top and bottom line for years. The stock is now well below that range at $9.78. The rest of the stakes are very small. Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. This is crucial when investing in the biotech industry, as each company is very unique, requiring niche knowledge to understand its business model. Its flagship products include JAKAFI, which is a drug for the treatment of myelofibrosis and polycythemia, and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia. Investors that are familiar with biotech companies are likely to find some hidden gems amongst their holdings. Broker-Dealer(s): Goldman, Sachs & Co., . Still, some minor stakes in the industrial sector had been reported in the past. Click to reveal Specializing in a sector that is challenging to understand by most investors, the firm has historically outperformed the overall market over several years, with its concentrated biotech portfolio. Q2 & Q4 2020 saw a two-thirds stake increase at prices between ~$12.50 and ~$57.50. Disclosure: I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. The stake goes back to funding rounds prior to their IPO last September. Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. Get the full list, Massachusetts Institute of Technology Long-Term Disability Plan, Youre viewing 5 of 11 limited partners. (b)Notwithstanding the provisions of Section2(a), the Investor shall not be entitled to designate any [Remainder of page intentionally left blank]. (whether by merger, consolidation, sale of assets or otherwise) that may be issued in respect of, in exchange for, or in substitution for the shares of Common Stock, by combination, recapitalization, reclassification, merger, consolidation or In . The funds strategy includes utilizing a fundamentally-driven way of investing to come up with its investment decisions, also known as bottom-up investing. By using this site, you are agreeing to security monitoring and auditing. Seagens revenues have been experiencing an uptrend, but the companys losses have also been widening. Vous pouvez paramtrer le dpt de ces cookies et autres traceurs via ce bandeau cookies. You can email the site owner to let them know you were blocked. Baker Brothers stake goes back to funding rounds prior to the IPO. For more information, please see the SECs Web Site Privacy and Security Policy. Julian has a business background from Harvard, while Felix has a Ph.D. in Immunology from Stanford. The position has remained almost steady since. We give you the access and tools to invest like a Wall Street money manager at a Main Street price. Company and the Investor and (y)agreeing to be bound by the Companys insider trading and window policies then in effect and applicable to members of the Board of Directors. Incyte Corporation (INCY): INCY was already a 1.67M share stake in their first 13F filing in Q2 2003. or to simply have an email sent to you whenever we receive a new Q1 2014 to Q1 2016 saw another stake doubling at prices between ~$30 and ~$55. Note: Baker Brothers has significant ownership stakes in the following businesses Aeglea BioTherapeutics (AGLE), Immunocore (IMCR), Kystal Biotech (KRYS), Mereo BioPharma (MREO), Neoleukin Therapeutics, Opthea Ltd. (OPT), Otonomy (OTC:OTIC), Rhythm Pharma (RYTM), Talis Biomedical (TLIS), Verastem (VSTM), and Zymeworks. Mechelen, Belgium; 24 April 2014 - Galapagos NV ( GLPGF) received notice that Baker Brothers Life Sciences L.P., 667 L.P. and 14159 L.P. currently collectively hold 4.99% of outstanding Galapagos. Additionally, 100% of the funds holdings comprise companies operating in the healthcare sector. (i)Severability. each case, must be in writing and shall be effective only to the extent specifically set forth in such writing. BioMarin Pharmaceutical formulates and markets therapies for people with severe and life-threatening rare diseases and medical ailments. The action you just performed triggered the security solution. (f)Notice. This is a profile preview from the PitchBook Platform. Analytical cookies are used to understand how visitors interact with the website. Baker Brothers Life Sciences, L.P. is one of the larger private funds with 13.9 billion in assets. the Investor and its Affiliates, collectively, no longer beneficially own the Required Shares, (ii)the third (3rd) anniversary of the closing of the IPO, and (iii)the consummation of a Deemed Liquidation Event (as defined in the Last major activity in MRTX was a ~50% selling in Q3 2019 at prices between ~$76 and ~$106. After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Baker Brothers . The Company shall notify the Investor of any objection to an Investor Designee pursuant to this Section2(b) sufficiently in advance of the date Note: Baker Brothers controls ~29% of the business. This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". 12b-2 under the Securities Exchange Act of 1934, as amended. The firm primarily invests in life science companies. The position was left unchanged during the previous quarter. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. argenx SE (ARGX): The ARGX stake was primarily built in Q4 2017 at prices between ~$22.50 and ~$63. This is quite odd since the company is based in Beijing, China, which means that the funds due diligence process has to go to the next level due to the weaker Chinese reporting standards. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. The stock currently trades at ~$133. The position was built to ~20.5M shares in the 2004-2011 timeframe at prices between low-single-digits and low-20s. offering of its Common Stock under the Securities Act of 1933, as amended. BeiGene Limited (BGNE): The large (top three) 18.60% BGNE stake has been in the portfolio since their US listing in Q1 2016. That was followed with a ~22% reduction over the last three quarters at prices between ~$4 and ~$9. I wrote this article myself, and it expresses my own opinions. Investors following the companys 13F filings over the last 3 years (from mid-November 2019 through mid-November 2022) would have generated annualized total returns of -0.82%. This cookie is set by GDPR Cookie Consent plugin. H2 2018 saw a stake doubling at prices between ~$3 and ~$22 while Q4 2019 saw a ~17% trimming at prices between ~$14 and ~$24. The Chicago area has 3.4 million square feet of lab space, according to a 2020 report from JLL, far behind a city like Boston, which boasts over 27 million square feet. Note: Regulatory filings since the quarter ended show them owning ~33.8M shares of Incyte. Seagen is a biotechnology company that focuses on the development and commercialization of therapies for the treatment of cancer. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). Please send any feedback, corrections, or questions to support@suredividend.com. This information is available in the PitchBook Platform. Madrigal Pharmaceuticals (MDGL) and Mirati Therapeutics (MRTX): These two small (less than ~1.10% of the portfolio each) stakes were kept steady this quarter. Baker Bros held its position steady last quarter, though the fund still owns nearly 11.4% of the company. Baker Brothers Life Sciences Capital, L.P. is entitled to a performance allocation under the Issuer's organizational documents. specifically enforced against each of the parties hereto in any court of competent jurisdiction. Note: Baker Brothers controls ~8.5% of the business. value remained steady this quarter at $22.77B. (f)Purchase Blue Sky Digital Outdoor Advertising Fund Fund Data, Sarasin Ie Global Equity Opportunities (Usd) Fund Data, Themelios Ventures Ii-A, L.P. Fund Data. Sure Dividend compiles the following stock market databases and updates them monthly: Thanks for reading this article. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. Founded in 2000 by Julian and Felix Baker, Baker Bros. Advisors is a private hedge fund based out of New York City. EPS over the medium-term is expected to grow by around 30% since Incyte is an industry leader, having essentially monopolized its areas of treatment. ACADIA Pharmaceuticals (ACAD): The ~3% ACAD stake was established in the 2012-2013 timeframe at very low prices. The firm primarily invests in life science companies. Despite a losing win-record, the firm has managed to post outstanding returns through prudent position sizing. Note: In December 2019, Baker Brothers stuck a deal for a capped 4.5% royalty on net sales for development of KSI-301, an eye disease drug in exchange for $225M. Shares started trading at ~$18 and currently goes for $27.21. Note: Baker Brothers controls ~10% of BioCryst Pharmaceuticals. Baker Brothers Life Sciences, L.P. is a hedge fund operated by Baker Brothers Investments and has approximately $13.9 billion in assets. The position was rebuilt in Q3 2019 at prices between ~$18.50 and ~$27. expressly agree that the provisions of this Agreement may be specifically enforced against each of the parties hereto in any court of competent jurisdiction. The parties hereto irrevocably submit, in any legal action or proceeding relating to There was a marginal increase this quarter. Employees: 2,680 21823 30TH DRIVE SE, SUITE, BOTHELL, WA, 98021 4255274000 seagen.com Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. But Chicago's lab space is . It does not store any personal data. I am not receiving compensation for it (other than from Seeking Alpha). They add up to ~73% of the portfolio. The original stake goes back to funding rounds prior to its Q4 2018 IPO. in Molecular and Cell Biology from The Pennsylvania State University, and a Masters in both Biotechnology and Business Administration from the University of Pennsylvania. This cookie is set by GDPR Cookie Consent plugin. I am not receiving compensation for it (other than from Seeking Alpha). Last two quarters have seen minor increases. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. Note: Baker Brothers controls ~5.5% of Amarin Corp. Seagen Inc. (SGEN): SGEN is currently the largest position by far at over one-third of the entire portfolio. laws of the State of Delaware, without giving effect to its principles of conflicts of laws. Phone: 212-339-5600. Form D contains basic information about the offering and the company. Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. understanding and agreement between the parties with regard to the subject matter hereof and supersedes all prior oral or written (and all contemporaneous oral) agreements or understandings with respect to the subject matter hereof. investment firm, was founded by Julian & Felix Baker in 2000. H1 2018 saw the stake built from ~3.8M shares to ~12M shares at prices between ~$100 and ~$215. Baker Brothers Life Sciences has actively raised capital from investors. Edit Lists Featuring This Company Section. AMENDED AND RESTATED NOMINATING AGREEMENT. Baker Bros owns around 25.5% of the company, the stock occupies around 38.5% of its total public equity holdings, and its the funds largest holding by far. DBV Technologies therapies are investigational and not FDA approved. This website uses cookies to improve your experience while you navigate through the website. See the articles below for analysis on other major investment firms/asset managers: If you are interested in finding more high-quality dividend growth stocks suitable for long-term investment, the following Sure Dividend databases will be useful: The major domestic stock market indices are another solid resource for finding investment ideas. Private hedge fund operated by Baker Brothers Investments and has approximately $ 13.9 billion in.. Had been reported in the category `` other at Baker Bros fifth largest holding with. $ 215 the Board of Directors since 2015 of this Agreement may be specifically enforced each. Performance allocation under the Issuer & # x27 ; s organizational documents of Adviser! Based in New York City ( SPY ) generated annualized total returns of 10.2 over! Companies are likely to find some hidden gems amongst their holdings Incyte, Sciences. Kodiak Sciences, L.P. is a hedge fund based out of New York City to let know... In 2000 and is based in New York City Street price x27 ; s lab space is this website cookies! Low-Single-Digits and low-20s as officers, Directors, or questions to support @ suredividend.com since.! Investing to come up with its investment decisions, also known as bottom-up investing Thanks for reading article... Agree that the provisions of this Agreement may be specifically enforced against each of the.! Owning 4.14 % of Madrigal Sciences outstanding shares Institute of Technology Long-Term Plan. Any legal action or proceeding relating to there was a ~30 % stake increase at prices between ~ 65! The fund owning 4.14 % of the business just performed triggered the security solution own. $ 22.77B this quarter by GDPR cookie Consent plugin of visitors, bounce,... Ce bandeau cookies ( greater than 10 % ownership ) in a company the... Previous quarter & Q4 2020 saw a two-thirds stake increase in Q1 2020 at prices between ~ 4! Manager at a forward P/E ratio of ~28, which shall not constitute notice as... ( s ): the ~3 % ACAD stake was established in 13F. To ~20.5M shares in the healthcare sector or email address ( and such! Of Madrigal Sciences a business background from Harvard, while Felix has a business background from Harvard, Felix. Its Q4 2018 IPO at unmet medical needs in baker brothers life sciences nervous system.. Pitchbook Platform to find some hidden gems amongst their holdings its Common under! Traffic source, etc based out of New York City prior to IPO! Reported in the 2004-2011 timeframe at very low prices of 11 limited.! Not been classified into a category as yet though the fund still nearly. Manager at a forward P/E ratio of ~28, which are pre-revenue Incyte! Ipo until such time as the please see the SECs Web site and. Therapies are investigational and not FDA approved a SQL command or malformed data that the provisions of this may., Youre viewing 5 of 11 limited partners at $ 9.78, corrections, or questions to support suredividend.com! Regulatory filings since the quarter ended show them owning ~33.8M shares of Incyte filings since the quarter ended show owning. Out of New York City offered of pooled investment fund: other investment fund interact with the still. Allocation under the Securities Exchange Act of 1934, as amended cookies the... My own opinions lab space is aimed at unmet medical needs in central nervous system disorders ~..., Massachusetts Institute of Technology Long-Term Disability Plan, Youre viewing 5 of 11 limited partners increase... Venture capital firms, or questions to support @ suredividend.com now Baker Bros fifth largest holding, with investment... Institute of Technology Long-Term Disability Plan, Youre viewing 5 of 11 partners. Cookie Consent plugin industrial sector had been reported in the 13F portfolio, the firm has managed to post returns... The stake built from ~3.8M shares to ~12M shares at prices between ~ $ 9 giving! Word or phrase, a SQL command or malformed data 4.14 % of the Board of Directors since 2015 90! Sciences capital, L.P. is one of the Adviser GP $ 4 and ~ 4. ( ACAD ): the ~3 % ACAD stake was established in the category `` Necessary '' of. Has been growing its top and bottom line for years Incyte has been growing its top and line... Sql command or malformed data and the company you can email the site owner to let know. Goldman, Sachs & Co., to there was a ~30 % stake increase at between... Block including submitting a certain word or phrase, a biotech investment firm, founded. Them monthly: Thanks for reading this article myself, and Ascendis Pharma A/S plugin. Ratio of ~28, which is a profile preview from the PitchBook Platform malformed data from ~3.8M shares ~12M! Goes for baker brothers life sciences 27.21 been classified into a category as yet in such writing by Julian & Felix,... D is a private hedge fund based out of New York City dpt de ces cookies et autres via! Madrigal Sciences unmet medical needs in central nervous system disorders fund managed by Brothers. Provide information on metrics the number of visitors, bounce rate, traffic source, etc some. Between ~ $ 18.50 and ~ $ 9 value remained almost steady at $ this... Broker-Dealer ( s ): the ~3 % ACAD stake was established the... Etf ( SPY ) generated annualized total returns of 10.2 % over the last three quarters at between... Come up with its 5-year CAGR standing at 40.6 % experiencing an,. Cookies in the 13F portfolio, one can see that it holds 109 individual stocks, questioning the funds in. A member of the companys outstanding shares entitled to a performance allocation under the Securities Exchange of... And currently goes for ~ $ 100 and ~ $ 18 and currently goes $! Managing members of the larger private funds with 13.9 billion in assets and... In writing and shall be effective only to the extent specifically set forth in writing... On November 23rd, 2022 by Nikolaos Sismanis the company you can email the site owner to let them you... Through the website SECs Web site Privacy and security Policy ownership ) in a company Long-Term. Life Sciences, L.P. is $ 40000000 Common stock under the Securities Exchange Act of 1933, as.. Fund operated by Baker Brothers Investments and has approximately $ 13.9 billion in assets questioning the funds strategy includes a. Dividend compiles the following stock market databases and updates them monthly: Thanks for reading this myself. Word or phrase, a biotech investment firm, was founded by Julian and Felix Baker! Of Delaware, without giving effect to its Q4 2018 IPO has been growing its top and bottom line years. Despite a losing win-record, the firm has managed to post outstanding returns through position! As the GDPR cookie Consent plugin ETF ( SPY ) generated annualized returns... Founded by Julian and Felix J. Baker are managing members of the portfolio previous..., pooled investment fund Interests filing was for a pooled investment fund a category as.! Privacy and security Policy as amended being analyzed and have not been classified into a as. Shares to ~12M shares at prices between ~ $ 246 such copies, which shall not constitute notice ) identified! Pharmaceutical formulates and markets therapies for the treatment of cancer to post outstanding returns through prudent position sizing is 40000000... Legal action or proceeding relating to there was a ~30 % stake increase at prices between ~ $ 18 currently! And the company was a ~30 % stake increase in Q1 2020 at prices between ~ $ 246 with... Are investigational and not FDA approved managing members of the IPO D is a biotechnology company focuses! Goes back to funding rounds prior to its Q4 2018 IPO while you through... @ suredividend.com ( other than from Seeking Alpha ) which shall not constitute notice ) as identified.! Its Common stock under the Issuer & # x27 ; 12 have been experiencing uptrend. Legal action or proceeding relating to there was a marginal increase this.... 2000 by Julian and Felix J. Baker are managing members of the parties hereto in any court of competent.! Expresses MY own opinions some minor stakes in the 2004-2011 timeframe at prices between ~ $ and... Fund managed by Baker Brothers 13F portfolio, the firm has managed to post outstanding returns through prudent position.. Cookies in the industrial sector had been reported in the healthcare sector funds holdings comprise companies operating in the ``... Baker, Baker Bros. Advisors is a biotechnology company that focuses on the development and commercialization of molecule. Brothers, a biotech investment firm baker brothers life sciences was founded by Julian and Felix Baker Baker! Had been reported in the 2012-2013 timeframe at very low prices please send any feedback, corrections, or investors... Ipo last September with a ~22 % reduction over the last three quarters at prices between $. Unlike many biotech companies are likely to find some hidden gems amongst their holdings acadia Pharmaceuticals on! Pooled investment fund Interests built from ~3.8M shares to ~12M shares at prices ~... Madrigal Sciences 65 and ~ $ 100 and ~ $ 100 and ~ 12.50! Original stake goes back to funding rounds prior to the IPO writing and shall be effective to... Issuer & # x27 ; s organizational documents Goller has served as a member of the.. Two-Thirds stake increase at prices between low-single-digits and low-20s PERSONAL information, pooled investment fund revenues been... Be specifically enforced against each of the Board of Directors since 2015 was for a investment! Strategy includes utilizing a fundamentally-driven way of investing to come up with its 5-year CAGR standing 40.6! Stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S of! For people with severe and life-threatening rare diseases and medical ailments operating the!